New drugs and treatment targets in psoriasis

Acta Dermato-Venereologica

Volumn 95, Issue 2, 2015, Pages 133-139

  Kofoed, Kristian ^a   Skov, Lone ^a   Zachariae, Claus ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Apremilast; Brodalumab; Ixekizumab; Psoriasis; Secukinumab; Tofacitinib; Ustekinumab

Indexed keywords

ADENOSINE RECEPTOR STIMULATING AGENT; APREMILAST; BRODALUMAB; IXEKIZUMAB; JANUS KINASE INHIBITOR; PHOSPHODIESTERASE INHIBITOR; SECUKINUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; ANTIINFLAMMATORY AGENT; BIOLOGICAL PRODUCT; DERMATOLOGICAL AGENT;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; INJECTION SITE ERYTHEMA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; ANIMAL; DRUG DESIGN; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL PRODUCTS; DERMATOLOGIC AGENTS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; PSORIASIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84925014280     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1931     Document Type: Review

References (32)

1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361: 496–509.
2. Herrier RN. Advances in the treatment of moderate-to-severe plaque psoriasis. Am J Health Syst Pharm 2011; 68: 795–806.
3. Seminara NM, Gelfand JM. Assessing long-term drug safety: lessons (re) learned from raptiva. Semin Cutan Med Surg 2010; 29: 16–19.
4. Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013; 168: 844–854.
5. Krueger JG, Fretzin S, Suarez-Farinas M, Haslett PA, Phipps KM, Cameron GS, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 2012; 130: 145–154.
6. Garcia-Perez ME, Stevanovic T, Poubelle PE. New therapies under development for psoriasis treatment. Curr Opin Pediatr 2013; 25: 480–487.
7. Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 2012; 11: 763–776.
8. Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs 2013; 22: 993–1005.
9. Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010; 10: 248–256.
10. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus- Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118–128.
11. Reich K, Langley RG, Papp KA, Ortonne JP, Unnebrink K, Kaul M, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 2011; 365: 1586–1596.
12. Langley RG, Papp K, Gottlieb AB, Krueger GG, Gordon KB, Williams D, et al. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol 2013; 27: 1252–1261.
13. Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013; 168: 412–421.
14. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366: 1190–1199.
15. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, et al. Brodalumab, an anti-interleukin- 17-receptor antibody for psoriasis. N Engl J Med 2012; 366: 1181–1189.
16. Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011; 332: 65–68.
17. Reich K, Ortonne JP, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab’ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol 2012; 167: 180–190.
18. World Health Organization Expert committee on biological standardization Guidelines on evaluation of similar biotherapeutic products (SBPs). Geneva, Switzerland. October 19–23, 2009.http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf. Accessed February 11, 2014.
19. Coherus Biosciences. Coherus announces CHS-0214 (proposed etanercept biosimilar) meets primary endpoint in pivotal pharmacokinetic clinical study (press release). http://www.coherus.com/press-releases/coherus-announces-chs-0214-proposed-etanercept-biosimilar-meets-primary-endpoint-in-pivotal-pharmacokinetic-clinical-study. Accessed February 11, 2014.
20. Schafer P., Parton A, Gandhi AK, Capone L, Adams M, Wu L, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010; 159: 842–855.
21. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 2012; 83: 1583–1590.
22. Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012; 380: 738–746.
23. Kaminska B, Swiatek-Machado K. Targeting signaling pathways with small molecules to treat autoimmune disorders. Expert Rev Clin Immunol 2008; 4: 93–112.
24. Hald A, Andres RM, Salskov-Iversen ML, Kjellerup RB, Iversen L, Johansen C. STAT1 expression and activation is increased in lesional psoriatic skin. Br J Dermatol 2013; 168: 302–310.
25. Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012; 167: 668–677.
26. Strober B, Buonanno M, Clark JD, Kawabata T, Tan H, Wolk R, et al. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol 2013; 169: 992–999.
27. Ports WC, Khan S, Lan S, Lamba M, Bolduc C, Bissonnette R, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 2013; 169: 137–145.
28. Barosi G, Rosti V. Novel strategies for patients with chronic myeloproliferative disorders. Curr Opin Hematol 2009; 16: 129–134.
29. Punwani N, Scherle P, Flores R, Shi J, Liang J, Yeleswaram S, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol 2012; 67: 658–664.
30. Fishman P, Bar-Yehuda S, Liang BT, Jacobson KA. Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today 2012; 17: 359–366.
31. David M, Akerman L, Ziv M, Kadurina M, Gospodinov D, Pavlotsky F, et al. Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol Venereol 2012; 26: 361–367.
32. Piali L, Froidevaux S, Hess P, Nayler O, Bolli MH, Schlosser E, et al. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther 2011; 337: 547–556.